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Integration of physiologically relevant in vitro assays at the earliest stages of drug discovery may improve the
likelihood of successfully translating preclinical discoveries to the clinic. Assays based on in vitro-differenti-
ated, human pluripotent stem cell (IVD hPSC)-derived cells, which may better model human physiology, are
starting to impact the drug discovery process, but their implementation has been slower than originally
anticipated. In this Perspective, we discuss imperatives for incorporating IVD hPSCs into drug discovery
and the associated challenges.Introduction
The cost of drug discovery has increased substantially in the past
several decades despite the number of new medicines reaching
themarket each year remaining essentially the same (Munos and
Chin, 2009). Many factors related to efficacy and safety have
contributed to this attrition and it seems clear that the drug dis-
covery industry must think differently about how new medicines
are developed from the earliest stages of drug discovery in order
to maintain a sustainable business model (Sams-Dodd, 2013;
Scannell et al., 2012). For the past 20 years, the drug discovery
industry, equippedwith a plethora ofmolecular targets, identified
from the sequencing of the human genome and advances
in combinatorial chemistry, has relied heavily upon high-
throughput screening (HTS) to identify biologically active small
molecules for further optimization into candidate drugs (Macar-
ron et al., 2011). Isolated catalytic protein domains and trans-
formed cell lines overexpressing the recombinant target protein
of interest are commonly used in HTS to facilitate the use of auto-
mation, simplify data analysis, and drive down costs.
This reductionist approach carries the risk that the assays do
not capture the full diversity of regulation seen in native cells. Iso-
lated catalytic domains potentially present small molecule-bind-
ing pockets that are different from what is present in full-length
native proteins or proteins that are in the presence of endoge-
nous binding partners. Conversely, the lack of a full-length pro-
tein may overlook allosteric regulators. For example, Goldin
et al. describe a small molecule HTS for activators and inhibitors
of the lysosomal enzyme glucocerebrosidase, which is deficient
in Gaucher disease (GD), using enzyme extracted from spleen
tissue of a GD patient carrying a common homozygous mutation
(Goldin et al., 2012). Comparison of the properties of the recom-
binant wild-type (WT) protein and the native mutant protein
showed differences in optimal pH andmaximal velocity for enzy-
matic activity. Compound screening found that approximately
92% of inhibitors identified in the WT enzyme screen were not
detected in the spleen extract screen and, conversely, approxi-
mately 97% of the activators in the spleen extract screen were
not detected in the WT enzyme assay. These differences could
be attributed in some instances to the endogenous presenceof SapC and phosphatidyl-serine in the spleen lysate. Another
issue to consider is that overexpression of isolated proteins at
nonphysiological levels in cell-based models can result in aber-
rant interactions or pathway alterations (Eglen et al., 2008). Com-
plex biological interactions with accessory proteins not present
in the engineered cell systems can also be potentially overlooked
(Lodge et al., 2010). In addition, homeostatic and compensatory
mechanisms that cells engage to cope with the stress of the dis-
ease state are ignored. Moreover, most in vitro toxicity testing is
performed in animal cells creating concerns about translatability
to humans (Knight, 2007). Collectively, these issues can result in
little relationship between in vitro assays and human clinical re-
sponses. Concerns regarding this risk have grown steadily
over the last decade as the failure to translate primary in vitro
pharmacology to the clinic has increased (An and Tolliday,
2010; Nolan, 2007).
New technologies, such as IVD hPSC-derived cells, have the
power to transform the drug discovery process. A slew of recent
papers have shown that cell-autonomous disease phenotypes
can be modeled in vitro. For example, both cardiac and neuro-
logical phenotypes associated with Timothy Syndrome, caused
by rare mutations in the L-type calcium channel Cav1.2, can be
detected in the terminally differentiated cells obtained from
patient hPSC, and these phenotypes can be reversed with phar-
macological treatment by roscovitine, a cyclin-dependent kinase
inhibitor and atypical L-type-channel blocker (Pasxca et al., 2011;
Yazawa et al., 2011). More recently, Garbes et al. (2013) showed
that IVD neurons from valproic acid (VPA)-resistant spinal
muscular atrophy patient hPSCs maintained VPA resistance
in vitro, which correlated with the clinical biomarker phenotype,
and the in vitro phenotype could be used to understand the
mechanism of VPA resistance. Liang et al. (2013) showed in a
collection of hiPSC-derived cardiomyocytes from patients with
hereditary cardiac disorders that they could replicate drug-
induced cardiotoxicities and detect differing susceptibility
among the patient-derived cells. These types of studies suggest
a paradigm in which patient biology and physiologically relevant
assays in human cells can drive drug discovery to deliver poten-
tially safer, more efficacious medicines.Cell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc. 669
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As the drug discovery industry adjusts to new realities, emphasis
is shifting away from the reductionist one-target one-drug one-
effect paradigm of the recent past and there is greater interest
in modulating pathways, interactomes, and cellular circuitry
(Chan and Loscalzo, 2012; Hart et al., 2012; Vidal et al., 2011).
Additionally, nontraditional drug target classes such as scaf-
folding, regulatory, and structural proteins are becoming more
attractive opportunities formodulating cellular function, and spe-
cifically designing drugs with targeted polypharmacology is
becoming realistic (Besnard et al., 2012; Makley and Gestwicki,
2013). This requires in vitro models that better address the
complexity found in vivo, with full-length proteins interacting
with their normal protein partners at the pathway and interac-
tome level and cocultures of communicating cell types at the
cell circuitry level.
Concurrent with the greater interest in biological networks,
there has been resurgent interest in phenotypic-based drug dis-
covery screens. Phenotypic screens lead to the identification of
molecules that affect an observable cellular characteristic by
acting on a previously undefined target or multiple targets simul-
taneously (Eggert, 2013). Despite significant gains in under-
standing the molecular basis of disease, many diseases with
significant unmet clinical needs still lack clear single-gene tar-
gets with an anticipated large impact on disease symptoms or
progression. For those diseases, identifying compounds or bio-
logics that alter specific disease-associated phenotypes may be
the best opportunity for disease modification or mitigation.
Furthermore, a recent analysis by Swinney and Anthony showed
that phenotypic screening was responsible for the identification
of 28 of 50 first-in-class small molecule drugs and 17 of 25 first-
in-class biologics (Swinney and Anthony, 2011). In order for
phenotypic screens to produce meaningful results, they require
the pathways, interactomes, and circuits necessary to produce
the phenotype of interest.
In 2008, the President’s Council of Advisors on Science and
Technology (PCAST) articulated the concept of ‘‘personalized
medicine,’’ which calls for basing medical treatment on a pa-
tient’s genetic makeup and specific disease characteristics
with the intention of increasing therapeutic benefits and
decreasing adverse effects (PCAST, 2008). The concept was
translated by the drug discovery industry into the related premise
of precision medicine. Precision medicine aims to integrate both
clinical and molecular information in order to better understand
the biological basis of disease and therefore select better disease
targets (Dolsten and Søgaard, 2012). When appropriate, specific
subpopulations of patients are identified that are more likely to
experience improved clinical outcomes and fewer side effects.
In order to move precision medicine from concept to practice,
various stakeholderswill need to collectively developappropriate
tools at the clinical stage, such as cost-effective means for
genomic analysis andprecision diagnostics, aswell as in vitro as-
says with superior clinical translation at the earliest stages of the
drug discovery process. These in vitro assays, which are the
basis for drug candidate selection, must incorporate genotypic
differences related to disease and ethnicity as well as the
complexity of human biological systems. Together, these
changeswill drive the use ofmodel systems at the earliest stages
of drug discovery that better model human in vivo conditions.670 Cell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc.Building More Physiologically Relevant In Vitro Assays
If physiologically relevant in vitro assays are to improve the likeli-
hood of successfully translating preclinical discoveries to the
clinic, a critical component will be the use ofmore physiologically
relevant cell systems that capture the complexity of the clinical
situation. Traditionally the term ‘‘physiologically relevant cells’’
has referred to the use of directly isolated primary cells from spe-
cies used in preclinical in vivo studies. Intuitively, the use of iso-
lated primary cells from either human or preclinical model spe-
cies seems to be the most appropriate in vitro model since the
cells are derived directly from the in vivo tissue of interest.
They have an advantage over engineered cell lines in that
expression of the target protein is regulated by native elements
and that proteins function in their normal environment; however,
primary cells also carry some significant disadvantages (Eglen
and Reisine, 2011). Terminally differentiated primary cells do
not proliferate, limiting the amount of material available for ex-
periments, and the large scale needed to conduct small-mole-
cule screening campaigns can preclude their use on practical
(cost, labor) and ethical grounds (Goldbard, 2006). Primary cells
often exhibit an unstable, dedifferentiating phenotype in culture
postisolation, which makes data interpretation difficult and limits
the available time window for experimentation (Sahi et al., 2010).
For some tissues, the current culture protocols are incapable of
recapitulating the cellular state of interest. For example, primary
neurons used for in vitro culture are generally isolated at very
early developmental stages, but young cells often fail to express
the relevant targets or functional phenotypes of mature neurons.
Human patient-derived primary cells are often confounded by
complex medical and treatment histories and donor-to-donor
variability is high. Even with animal-derived cells, preparation-
to-preparation variability is high, and it is not uncommon for a pri-
mary cell preparation to fail to exhibit a functional response.
To complicate matters further, differences between human
and animal physiology have made researchers more cautious
about using primary animal cells (Greek and Rice, 2012; van
der Worp et al., 2010). Coupled with the fact that most animals
do not naturally develop human disorders, such as Alzheimer’s
disease and metabolic syndrome, and genetically modified ani-
mals tend to mimic only limited aspects of a given disorder, re-
searchers have becomemore interested in using human primary
cells. Although human cells have recently become more acces-
sible through commercial sources, patient-specific tissue and
cells are still often difficult and costly to obtain. For some dis-
eases such as neurodevelopmental or neurodegenerative disor-
ders, live cultures of the target cell type (e.g., neurons) are almost
completely inaccessible, and since development of these dis-
eases are thought to be a process that occurs over time, post-
mortem tissue can only provide a snapshot of the end stage
with minimal elucidation of the biochemical events leading up
to it.
Thegenerationof humanembryonic stemcells (hESCs) (Thom-
son et al., 1998) and more recently human-induced pluripotent
stem cells (hiPSCs) (Takahashi et al., 2007a, 2007b; Yu et al.,
2007) has offered an alternative to human primary cells for use
in drug development. These cells have unlimited proliferation ca-
pacity in the undifferentiated state and are genetically stable dur-
ing prolonged passage. Under appropriate culture conditions,
the cells can be directed to differentiate into a variety of terminal
Figure 1. Patient-Driven Drug Discovery
Human pluripotent stem cells derived from patients have the potential to transform drug discovery by providing physiologically relevant cells in the quantity
necessary to support the in vitro assays used to understand basic mechanisms of disease and to identify safe and efficacious clinical compounds as well as
iteratively relating patient information from the clinic back to the drug discovery laboratory.
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process recapitulates aspects of normal development, opening
up theopportunity to studydevelopmental anddegenerative pro-
cesses. Unlike primary cells, stem cell-derived cells exhibit a
more stable phenotype in long-term culture that is representative
of the in vivo cell. The culturing of the cells in both the undifferen-
tiated and differentiated state is amenable to automation and is
scalable, suggesting that supply, demand, and cost could be
balanced. Since hiPSC can be generated via epigenetic reprog-
ramming of adult somatic cells, there is an exponentially
increasing number of genetically diverse and patient-specific
cells. This expanding pool allows for direct testing of potential
new drugs in samples from target populations, thus directly sup-
porting initiatives in precision medicine. The undifferentiated
hiPSCs can be genetically modified through a variety of methods
including electroporation, viral transduction, transposons, zinc
finger nucleases, and transcription activator-like effector nucle-
ases (TALENs) in order to introduce selection cassettes to help
drive differentiation along a specific lineage (Cheng et al.,
2012). Additionally, the incorporation of biosensors, reporters,
and tagged proteins enables assay of endogenous endpoints.
IVD hPSC-Derived Cells for Drug Discovery
The use of IVD hPSC-derived cells as tools for aiding drug dis-
covery has been met with great enthusiasm by drug discoverersand commercial reagent and service providers alike. This inter-
est is separate from the interest in the regenerative medicine
field, which focuses on using stem cells as therapies or targets
for therapies. The use of IVD hPSC-derived cells as drug discov-
ery tools is viewed as more immediate, practical application of
the technology (Cezar, 2007; Rowntree andMcNeish, 2010; Sar-
tipy et al., 2007). Many examples have now been reported of IVD
hPSC-derived cells from patients with monogenic disorders or
engineered disease gene mutations recapitulating disease phe-
notypes in vitro (Merkle and Eggan, 2013). These cells offer a
potentially physiologically relevant, cost effective way to
continue to practice high-throughput and structure-activity rela-
tionship (SAR) screening within the existing drug discovery para-
digm, with less inherent variability than primary cell cultures
(Figure 1). Unlike primary cells, the IVD hPSC-derived cells are
available in essentially unlimited quantities and can be delivered
on a predictable timetable over the 2–5 years necessary to run a
drug candidate selection program. For commercial reagent and
service providers, opportunities exist to grow, differentiate, char-
acterize, and supply these cell reagents to support drug discov-
ery efforts. Several high-profile collaborations have been struck
between drug discovery companies and service providers or
leading stem cell academic centers (Baker, 2010). Biotech com-
panies such as Fate Therapeutics and iPierian were founded to
exploit the cutting edge IVD hPSC-derived cell technology forCell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc. 671
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The current thinking is that the first companies to implement
stem cell-based technologies will have a competitive advantage
in the market place either as reagent/service providers or in the
delivery of efficacious drugs with a good safety profile.
While IVD hPSC-derived cells, in theory, could be differenti-
ated into any human cell type, early efforts have been concen-
trated in four areas: cardiomyocytes, hepatocytes, neurons,
and pancreatic beta islet cells. These four cell types have
been studied extensively by developmental biologists and
much is known about the molecular and biochemical signals
driving their differentiation in vivo (Gittes, 2009; Si-Tayeb
et al., 2010; Van Vliet et al., 2012; Vieira et al., 2010). Human
cells from these tissues are particularly difficult to culture, costly
to obtain, and limited in number. For drug discovery companies,
these cell types represent the greatest immediate need. Cardi-
otoxicity and hepatotoxicity together are the leading cause of
failure and/or withdrawal of preclinical and postmarketed drugs
(Lasser et al., 2002; Schuster et al., 2005). Neurological disor-
ders and diabetes are responsible for an increasing proportion
of morbidity and mortality (American Diabetes Association,
2013; Olesen et al., 2012). The limited availability of primary tis-
sue from the four cell types means that in vitro assays using
these cells are low throughput, thus limiting their application
to drug discovery (Allen et al., 2010; Sandusky et al., 2009).
This limitation creates a gap that could be filled by the develop-
ment of medium- to high-throughput in vitro assays based on
IVD hPSC-derived cells. These assays could be used earlier in
drug discovery for evaluating larger numbers of compounds.
For research areas such as oncology and immunology, which
have relatively easier access to their primary target tissues
(for example, tumors or hematopoietic progenitor cells) and
well-established methods for amplifying and propagating the
cells, IVD hPSC-derived cells are of less interest. For these
applications, the need to develop better human models is less
urgent. Taken together, these considerations have led drug dis-
coverers to focus on acquiring or generating hPSC- or IVD
hPSC-derived cells to develop assays using one of these four
cell types.
Challenges to Implementing IVD hPSC-Derived Cell
Models in Drug Discovery
With clear gaps to be filled and strong incentives, it was ex-
pected that IVD hPSC-derived models would be rapidly inte-
grated into the drug discovery process. The pace, however,
has been slower than first anticipated. While each drug discov-
ery company faces its own issues in implementing the technol-
ogy, several common concerns have probably impacted all
companies to a greater or lesser extent.
Introduction of New Technology
For any organization, the process of implementing new technol-
ogy can be difficult and the introduction of IVD hPSC-based drug
screening is no different (Leonard-Barton and Kraus, 1985). Sup-
port is required from organization leaders as well as project
teams. While a handful of advocates at both levels may actively
promote the technology, a much larger community may not be
fully familiar with the advantages and limitations of new technol-
ogy. While the authors are most familiar with their own company,672 Cell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc.anecdotal stories from colleagues in other pharmaceutical com-
panies suggest this challenge is not unique.
For organizational leaders, there is a need to understand howa
stem cell-based technology will address identified gaps and the
expected time frame in which a technology, if implemented, will
affect the success rate of potential new drugs reaching the clinic.
As with any new technology, this is difficult to predict or substan-
tiate with data early in the implementation process. Enthusiasm
for a new technology can wane with protracted timelines to
tangible results or the reprioritization that is common in the phar-
maceutical industry. In an effort to maintain the enthusiasm,
there is a danger of overselling the advantages or likely time to
impact of a technology by both internal and external advocates.
While this may have short-term benefits for bolstering support,
poor management of expectations can be detrimental if a new
technology fails to perform as promised.
The introduction of IVD hPSC-based assays creates a conun-
drum for project team leaders as well—stick with an established
assay or embark on developing a potentially more informative
assay with no guarantee of success. Established assays, while
having their limitations, have undergone extensive validation
with significant historical information on how test compounds
performed in the in vitro assays and how those results translate
to in vivo findings. Data derived from new technology such as
IVD hPSC-based assays lack historical context and generating
that information is time consuming, expensive, and carries no
guarantee that the data generated will be any more relevant or
informative. While the IVD hPSC-based assays avoid the known
complications inherent in immortalized cell lines, they carry with
them new uncertainties. Specifically, it is not clear how closely
these artificially derived cells model the identity and function of
fully differentiated adult cells from normal or diseased individ-
uals. Thus, it can be unclear how to interpret the data and how
to quantify the potential risk of false positives (or negatives). Proj-
ect teams can be facedwith generating data concurrently in both
the old and new technology in order to build confidence in the
new technology and can find it difficult to relinquish the older
assay and base decision making solely on the IVD hPSC-based
assay. Given that project teams are often required to report proj-
ect progress every 3–6 months, justify continued support of their
project in relationship to the larger project portfolio, and operate
with a limited budget, it can be very difficult for them to even pilot
the new technology.
For any new technology to take hold within an organization,
there has to be a compelling reason for investment. Specifically,
the technology must generate information that cannot be ac-
quired by any other method, thus providing a competitive advan-
tage to the organization. It must provide novel biology or allow
the development of assays in physiologically relevant cell sys-
tems that were once inconceivable due to cell limitations. The
overall gain in informationmust be proportional to the associated
investment costs. In a resource-constrained research and devel-
opment environment, the technology must provide data signifi-
cantly faster or more cost effectively. If the costs, including
both direct (for example, purchasing IVD hPSC-derived cells)
or indirect (for example, labor or equipment), are significantly
higher for obtaining the same information or quality of data, there
is no justification for adopting the new technology. Equivalency
is not enough.
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Utilization of hPSCs in the pursuit of drug discovery has been
constrained by legal issues since the derivation of the first
hESC in 1998. Controversies over the embryonic source of
hESC has led to widely varying policies among countries
regarding the use of these cells ranging from outright prohibition
to financial incentives to conduct research (Campbell and
Nycum, 2005; De Trizio and Brennan, 2004). Facing uncertain
social sentiment from shareholders and consumers and a patch-
work of laws, particularly in the United States, drug companies
have often been hesitant to invest in hESC work. Additionally,
a licensing agreement is necessary to obtain access to hESC
since most laboratories do not have the reagent access, skills,
or interest necessary to generate their own (Gulbrandsen,
2007; Levine, 2011).
In 2007, with the development of hiPSC methods, and the fact
that many laboratories have the appropriate skill sets to generate
their own hiPSC lines, access to hPSCs became more wide-
spread. Since hiPSCs are generated from adult tissues, the
ethical concern regarding the use of embryo-derived material
was removed. The murky patent landscape, with multiple poten-
tially competing patent applications, made it possible to initially
develop the technology while waiting for the intellectual property
landscape to become clearer. This trend has subsequently
evolved more openly and collaboratively (Georgieva and Love,
2010) but that is not to imply that hiPSC use is not without its
own legal obstacles. Reagent and cell service providers have
been quick to commercialize reagents and services for the
generation and/or differentiation of iPSCs. These reagents and
services have often been generated with multiple underlying
technologies covered by amyriad of patents, thusmaking it diffi-
cult to determine freedom to operate. Likewise, developing an
appropriate informed consent process for tissue donors has
required addressing complex issues associated with the immor-
tality of the cells, their intimate connection to the health informa-
tion of specific individuals, and their unprecedented scientific
potential (Lowenthal et al., 2012). Because many iPSC lines
have been generated with patient material that was already in
the possession of researchers prior to the development of new
consent forms, access to or use of these lines for drug discovery
efforts can be limited.
Cell-Based Issues
Perhaps the most critical issue for adapting IVD hPSC-derived
cell models for efficacy and toxicity testing is the production
and performance of the cells. Generation of IVD hPSC-derived
cells is a developing technology predicated on the understand-
ing of the complexities of developmental biology. An ever
increasing number of IVD protocols, mostly for cardiomyocytes,
hepatocytes, neurons, and pancreatic beta islet cells, are being
published (for example, see Chambers et al., 2009; Czepiel et al.,
2011; Lian et al., 2013; Song et al., 2009; Tohyama et al., 2013;
Zhang et al., 2009). These protocols vary in their repeatability
and robustness in generating scalable, homogenous cell popula-
tions. It is often difficult to determine whether the variation in cell
production is due to differences in laboratory culture conditions,
cell lines used, seeminglyminor protocol changes, or a combina-
tion of all three. In vitro differentiation protocols for many other
cell types are lacking. When the phenotypes of IVD hPSC-derived cells are characterized, they most often are develop-
mentally immature compared to their in vivo-derived counter-
parts and may lack full functionality. As one example, Song
et al. (2009) describe the generation of hiPSC-derived hepato-
cytes, which, at day 21, exhibited typical liver cell functions
including albumin A secretion, glycogen synthesis, urea produc-
tion, and inducible cytochrome postnatal day 450 (P450) activity;
however, the levels were on average 10- to 20-fold less than
seen in human primary hepatocytes recovered from cryopreser-
vation. Coalitions of researchers with diverse expertise in areas
such as developmental biology, immunohistochemistry and
flow cytometry, gene expression, and cell type-specific func-
tional assays are necessary to characterize the cells, to interpret
their relationship to in vivo tissue, primary cells, or other cells in
use, and to determine whether the IVD hPSC-derived cells have
the characteristics necessary to evaluate the endpoint(s), pheno-
type(s), or pathway(s) of interest (Rao, 2013). This evaluation be-
comes significantly more difficult if the minimal criteria for utility
are poorly defined or the IVD hPSC-derived cells are being
compared to an idealized ‘‘gold standard,’’ as the cells will
almost always fail to live up to expectations.
Production of the appropriate cell type can be a protracted
process that is not well aligned with the pace of the drug discov-
ery process. Undifferentiated hPSC culture and development of
in vitro differentiation protocols require meticulous attention to
detail and a wide array of traditional and nontraditional cell cul-
ture techniques. Time and practice are required for individuals
to build proficiency in these techniques and a pool of trained
hPSC biologists has not always been readily available in a phar-
maceutical environment. Many early stem cell techniques such
as passaging of undifferentiated hPSCs as small clusters on a
fibroblast monolayer were labor intensive and not amenable to
scale-up or automation, consequently slowing project progres-
sion. In vitro differentiation protocols require weeks, if not
months, to generate the cell types of interest, thus limiting exper-
imental cycle times (Nicholas et al., 2013; Yi et al., 2013). Each
technical advance in this rapidly evolving field, even seemingly
minor ones such as changes in media components, require
time-consuming validation to confirm that pluripotency and/or
differentiation capacity are maintained. Long development time-
lines need to be incorporated into plans if the IVD hPSCmodel is
to have an impact on the project and not become irrelevant as
the project progresses and the IVD hPSC-derived cells lag.
From the standpoint of precision medicine, the magnitude of
this problem increases as multiple cell lines will need to be
generated, differentiated, and characterized to assess target
populations. Although acquiring IVD hPSC-derived cells from a
cell reagent provider can reduce internal efforts and timelines
at the stage of generating the cells, their characterization, assay
development, and validation can still be significant (see below).
Assay-Based Issues
Cell-based small molecule screening assays in the drug discov-
ery industry have evolved a pattern of using nearly unlimited,
hearty, homogenous cryopreserved cells that require minimal
handling postthaw and prior to running the assay. IVD hPSC-
derived cell models do not easily fit into this system, and the
list of potential caveats is extensive. Handling of IVD hPSC-
derived cells can be more labor intensive and time consuming.Cell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc. 673
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preservation, resulting in low recovery postthaw and, in theworst
cases, differentiation must be initiated from the start for each
use. Almost all IVD hPSC-derived cells require culturing post-
thaw to develop a functional phenotype and the appropriate
time frame for the assay must be determined with extensive
testing and validation. For example, cryopreserved IVD cardio-
myocytes may take up to 14 days to reestablish a stable pheno-
type based on morphology and gene expression (Puppala et al.,
2013). The cells themselves can be fragile, requiring manual
handling or specialized equipment to prevent dislodging or cell
damage. The assay window may be quite small because the
cells express proteins at physiological levels, and more sensitive
detection equipment or reporter systems may be necessary.
Variation in cellular performance can be quite high, further
obscuring weak signals. Three-dimensional culture conditions
or cocultures of interacting cells may be necessary to realize a
phenotype fully representing in vivo biology, creating concerns
regarding equal access of compounds to cells and differential
metabolism.
Despite hopes of unlimited numbers of relatively inexpensive
cells, the availability of IVD hPSC-derived cells has been limited
by less-than-robust production protocols and/or the relatively
high cost of obtaining cells from cell providers. Fewer cells
mean that project teams, accustomed to evaluating large
numbers of compounds, must think differently about how to
find biologically active molecules and determine SAR in order
to match the available assay throughput. For biologists, this
means miniaturizing assays through the development of nanoli-
ter technologies or increasing information acquisition through
imaging or single-cell technologies. In this respect, miniaturiza-
tion can be problematic if the cells causing the response are a
small proportion of a heterogeneous cell population, as the
response can be lost if the cell number is decreased past a crit-
ical point. For chemistry, new approaches mean relying on more
rational design of compounds and in silico modeling tomaximize
information while minimizing the number of compounds synthe-
sized.
The use of patient-derived IVD hPSCs creates an additional
challenge not typically encountered when using recombinant
proteins or engineered cell assay systems. Because each IVD
hPSC model represents a unique patient who may or may not
represent the ‘‘typical’’ disease, it is important to have as much
clinical information including disease course, treatments, co-
morbidities, and family health histories and genotypic informa-
tion (potentially including full exome or genome sequencing on
the patient) as possible to ensure that results of the assay will
have relevance to others with the same disease. Seemingly use-
ful small molecules or findings from the initial screen will likely
need to be followed upwith screens from IVD hPSC assays using
different patient cells that represent both close-in comparisons
(for example, similar genetic mutations or constellation of symp-
toms for those diseases without known genetic mutations) as
well as more distant comparisons (for example, different genetic
mutations leading to the same disease or mild versus severe
symptoms within the spectrum of a disease) (Yang et al.,
2013). Although, the depth of follow-up will probably vary with
the drug target, panels of high-quality, patient-derived hPSCs
representing the diversity of the disease will be necessary,674 Cell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc.thus increasing both the time and cost to set up the assay as
well as execute it.
Future Use of IVD hPSC-Derived Cells in Drug Discovery
Despite the challenges associated with integrating IVD hPSC-
derived cells into drug discovery, the potential of these cells to
radically improve the translatability of information leading to
the clinic means that those involved in drug discovery will
continue to invest and progress this technology. As outlined in
Figure 2, there are several stages in the drug discovery process
in which IVD hPSCs are currently being utilized and several more
opportunities in which these cells can be integrated. The current
use of hPSCs in drug discovery is almost exclusively at the
earliest stage in which IVD hPSCs are being used to investigate
disease biology or as a cell source for compound, efficacy, and
toxicity screening. Asmore genetically diverse hPSCs and better
cell IVD protocols become available, it is easy to imagine that IVD
hPSC-derived cells will find uses in modeling differences in drug
absorption, metabolism, and elimination that are associated with
genetic variation in cytochrome p450 enzymes and transporters.
This information could potentially impact where clinical trials are
held and who is accepted into the trial such that investigational
new drugs (INDs) are tested only in the patients whose pharma-
cokinetic/pharmacodynamic profile suggest that they are most
likely to receive a benefit and least likely to experience an
adverse event (Fakunle and Loring, 2012). As the cost decreases
and the efficiency of hiPSC line generation increases, drug com-
panies may find it beneficial to prospectively collect samples for
iPSC generation from even late-stage (phase III) clinical trials.
This may allow companies to retrospectively evaluate idiosyn-
cratic adverse findings or further refine their understanding of
what identifies or determines those patients who benefit from
the drug. Importantly, the collection of hiPSCs generated from
a clinical trial will be an available resource for testing new drugs.
This wouldmake it possible to use essentially the same, clinically
well-documented patient cohort in multiple ‘‘in vitro clinical tri-
als,’’ further strengthening the understanding of the interaction
between genotype, phenotype, and drug response.
Many of the strategic, legal, and technical challenges associ-
ated with the IVD hPSCs are being addressed. Multiple organ-
izations (Europe’s Innovative Medicines Initiative, California
Institute of Regenerative Medicine, New York Stem Cell Founda-
tion, etc.) are thoughtfully and proactively generating appropri-
ately consented hiPSCs with well-documented clinical histories
and corresponding comprehensive genetic information and are
making them available with limited restrictions through clear dis-
tribution channels for use in drug discovery. Improved methods
of generating hiPSCs, which rely on more clinically available ma-
terial such as blood and do not have integration of foreign ge-
netic material into the cells, have been developed (Fusaki
et al., 2009; Warren et al., 2010; Yu et al., 2009). Efforts around
increasing reprogramming efficiency and applying automated
methods are helping to drive down the costs of generating
hiPSCs to the point where it is conceivable to begin using
them to evaluate patient responses in clinical trials. Similarly, ad-
vances in generating large quantities of both undifferentiated
hPSCs and terminally differentiated cells types using automa-
tion-friendly culturing conditions have helped increase the cell
supply and reduce variability and manage costs. The realization
Figure 2. Integration of IVD hPSC-Derived Models into Drug Discovery
IVD hPSC-derived models have the potential to significantly impact the entire drug discovery value chain. The current use of IVD hPSC-derived models has
focused on the very early, preclinical stages of drug discovery. As the technology progresses and the costs to generate patient cells and models decreases, it is
likely that the technology will find additional applications at the clinical trial stage and in postmarketing surveillance. IND, investigative new drug; NDA, new drug
application.
Cell Stem Cell
Perspectivethat full characterization of the IVD hPSC-derived cell type is crit-
ical to planning and interpreting experiments has led to calls for
clearly defined standards for defining each cell type and greater
upfront investment by individual laboratories and cell providers
to understand the biology of the cells being generated. Even un-
der the most optimistic scenarios, it is unlikely that IVD hPSC-
based models will ever totally supplant isolated protein assays,
engineered cells models, or in vivo models. However, each of
the advances described above, while individually tackling a sin-
gle aspect of the technology, together makes it more likely that
IVD hPSC-derived cells become a staple of drug discovery and
not a niche application.
As the use of IVD hPSC-based models grows, we predict that
examples of successful application of the technology will be
more readily available. Early forays into using IVD hPSC-based
models have helped researchers build a realistic understanding
of the advantages and disadvantages of the technology. Project
teams are already better positioned to assess whether an IVD
hPSC model is the right model to address the question at hand
and to position it appropriately. There is also a better under-
standing of how to match the functionality of the cells with the
assay and a willingness to develop fit-for-purpose assays that
take advantage of the cell capabilities but that may not fit the
traditional drug discovery screening paradigm. As progress ismade, governmental regulatory bodies (for example, the FDA)
will better understand how the assays inform questions around
efficacy and safety, and organizational leaders will potentially
see the impact on clinical success of new drug candidates.
Most importantly, patients should receive the most benefit with
the better drugs that result from IVD hPSCs, as they would be
selected for them to have the greatest efficacy with the fewest
side effects.
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